Abstract
Kidney transplantation is being performed more frequently for individuals with end stage renal disease (ESRD) due to improved survival and quality of life compared to long-term dialysis. Though rates decrease after transplant, cardiovascular disease (CVD) remains the most common cause of death after kidney transplant. New-onset diabetes after transplant (NODAT), a common complication following kidney transplantation, and pre-transplant diabetes both significantly increase the risk for CVD. Several other risk factors for CVD in kidney transplant recipients have been identified; however, optimal therapy for controlling the risk factors of CVD after kidney transplantation, including NODAT and pretransplant diabetes, is not well defined. In the following review we will discuss the role of traditional and non-traditional risk factors in CVD after kidney transplant and the mechanisms involved therein. We will also examine the current literature regarding treatment of these risk factors for the prevention of CVD. Finally, we will review the current recommendations for pre- and post-transplant cardiovascular evaluation and management.
Keywords: Diabetes, Hypertension, Dyslipidemia, Obesity, Cardiovascular disease, Kidney transplant, End stage renal disease, New-onset diabetes after transplant, Chronic kidney disease (CKD), Hyperparathyroidism, Hyperhomocysteinemia, Hyperuricemia
Current Diabetes Reviews
Title: Diabetes and Cardiovascular Disease Following Kidney Transplantation
Volume: 7 Issue: 4
Author(s): Brian P. Boerner, Vijay Shivaswamy, Cyrus V. Desouza and Jennifer L. Larsen
Affiliation:
Keywords: Diabetes, Hypertension, Dyslipidemia, Obesity, Cardiovascular disease, Kidney transplant, End stage renal disease, New-onset diabetes after transplant, Chronic kidney disease (CKD), Hyperparathyroidism, Hyperhomocysteinemia, Hyperuricemia
Abstract: Kidney transplantation is being performed more frequently for individuals with end stage renal disease (ESRD) due to improved survival and quality of life compared to long-term dialysis. Though rates decrease after transplant, cardiovascular disease (CVD) remains the most common cause of death after kidney transplant. New-onset diabetes after transplant (NODAT), a common complication following kidney transplantation, and pre-transplant diabetes both significantly increase the risk for CVD. Several other risk factors for CVD in kidney transplant recipients have been identified; however, optimal therapy for controlling the risk factors of CVD after kidney transplantation, including NODAT and pretransplant diabetes, is not well defined. In the following review we will discuss the role of traditional and non-traditional risk factors in CVD after kidney transplant and the mechanisms involved therein. We will also examine the current literature regarding treatment of these risk factors for the prevention of CVD. Finally, we will review the current recommendations for pre- and post-transplant cardiovascular evaluation and management.
Export Options
About this article
Cite this article as:
P. Boerner Brian, Shivaswamy Vijay, V. Desouza Cyrus and L. Larsen Jennifer, Diabetes and Cardiovascular Disease Following Kidney Transplantation, Current Diabetes Reviews 2011; 7 (4) . https://dx.doi.org/10.2174/157339911796397857
DOI https://dx.doi.org/10.2174/157339911796397857 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Endothelin-1 Actions on Vascular Smooth Muscle Cell Functions As a Target for the Prevention of Atherosclerosis
Current Vascular Pharmacology Use of microRNAs as Anti-Atherosclerosis
Mini-Reviews in Medicinal Chemistry Treatment Strategies for Fatty Liver Diseases
Reviews on Recent Clinical Trials Memantine: Its Role in Vascular Dementia
Drug Design Reviews - Online (Discontinued) RNAi in Clinical Studies
Current Medicinal Chemistry Atrial Fibrillation with a Focus on Oral Antiarrhythmic Therapy
Current Drug Therapy Altered Steroid Metabolism and Insulin Signaling in PCOS Endometria: Impact in Tissue Function
Current Pharmaceutical Design Anti-Inflammatory and Antioxidant Effects of Resveratrol in Healthy Smokers A Randomized, Double-Blind, Placebo-Controlled, Cross-Over Trial
Current Medicinal Chemistry Comparative Study of Nutritional and Phytochemical Attributes of Andrographis paniculata, Bryophyllum pinnatum and Clitoria ternatea for Nutraceutical Applications
Current Nutrition & Food Science Patent Selections
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Synthesis of Novel 3(N,N-dialkylamino)alkyl/phenyl Substituted Thieno [2,3-d]pyrimidinones as H1-Anti-Histaminic and Antimicrobial Agents
Current Bioactive Compounds Synthesis and Cholinesterase Inhibition Activity of New Pyrrolopyrimidine Derivatives
Letters in Drug Design & Discovery Antimicrobial and Antioxidant Activity of Micromeria Bentham Species
Current Pharmaceutical Design Renal Blood Flow Dynamics in Inbred Rat Strains Provides Insight into Autoregulation
Current Vascular Pharmacology Inhaled Insulin and the Lung
Current Medicinal Chemistry Nano-constructed Carriers Loaded With Antioxidant: Boon For Cardiovascular System
Current Pharmaceutical Design Patients’ Illness Perceptions of Type 2 Diabetes: A Scoping Review
Current Diabetes Reviews Pharmacology and Literature Review Based on Related Death and Non-Fatal Case Reports of the Benzofurans and Benzodifurans Designer Drugs
Current Pharmaceutical Design Gene and Stem Cell Therapy in the Treatment of Erectile Dysfunction and Pulmonary Hypertension; Potential Treatments for the Common Problem of Endothelial Dysfunction
Current Gene Therapy TGF-β Receptor Signaling Pathways in Angiogenesis; Emerging Targets for Anti-Angiogenesis Therapy
Current Pharmaceutical Biotechnology